Rol del cardiólogo en el manejo de pacientes oncológicos. ¿Dónde estamos y a donde debemos ir?

Cynthia Paredes-Paucar; Teresa López-Fernández

doi:10.47487/apcyccv.v2i2.140

Autores/as

Cynthia Paredes-Paucar Unidad de cuidados coronarios. Instituto Nacional de Cardiología Ignacio Chávez. México. https://orcid.org/0000-0003-0734-6437
Teresa López-Fernández Servicio de cardiología, unidad de cardio-Oncologia del hospital universitario La Paz. Instituto de investigación La Paz-IdiPAz, Madrid, España.

DOI:

https://doi.org/10.47487/apcyccv.v2i2.140

Palabras clave:

Toxicidad, Insuficiencia cardiaca, Oncología

Resumen

Las enfermedades cardiovasculares y las enfermedades oncológicas constituyen la primera y segunda causa de muerte a nivel mundial. Los pacientes oncológicos tienen más riesgo de muerte cardiovascular, y los pacientes cardiacos tienen más riesgo de cáncer, y esta interrelación va más allá de la toxicidad relacionado al tratamiento oncológico. La cardio-oncología surge como subespecialidad capaz de manejar las complicaciones cardiovasculares en pacientes con cáncer. Entre ellas, la disfunción cardiaca relacionada con antitumorales es una de las más temidas, y requiere una estratificación, diagnóstico, tratamiento y seguimiento oportuno. La creación de servicios cardio-oncológicos es una realidad que debemos construir a fin de cambiar nuestra práctica clínica y política sanitaria actual, con claras implicaciones a futuro.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

Health at a Glance 2019. OECD Indicators. [internet]. OECD.org [Publicado 07 de noviembre, 2019. Última visita 30 de abril 2021]. Disponible en Health at a Glance 2019: OECD Indicators | en | OECD

Análisis de situación de salud del Perú 2019. [internet]. Centro Nacional de Epidemiología, Prevención y Control de enfermedades. [Publicado diciembre 2019. Última visita 30 de abril 2021]. Disponible en: Análisis Situación Salud Perú.indd (dge.gob.pe)

Cardinale D. A new frontier: cardio-oncology. Cardiologia [Internet]. 1996; 41:887-91.

Cardinale D, Caruso V, Cipolla CM. The breast cancer patient in the cardioncology unit. J Thorac Dis 2018 [Internet]. Dec;10(Suppl 35): S4306-S4322. DOI: 10.21037/jtd.2018.10.06

Meijers WC, Rudolf A. de Boer. Common risk factors for heart failure and cancer. Cardiovasc Res [Internet]. 2019 Apr 15;115(5):844-853. DOI: 10.1093/cvr/cvz035

Moslehi J, Zhang Q, Moore KJ. Crosstalk Between the Heart and Cancer Beyond Drug Toxicity. Circulation [Internet]. 2020 Aug 18;142(7):684-687. DOI: 10.1161/CIRCULATIONAHA.120.048655

López-Fernández T, García AM, Santaballa Beltrán A, et al. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Rev Esp Cardiol (Engl Ed) [Internet]. 2017 Jun;70(6):474-486. DOI: 10.1016/j.rec.2016.12.041

Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J [Internet]. 2019 Dec 21;40(48):3889-3897. DOI: 10.1093/eurheartj/ehz766

MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J [Internet]. 2008 Jun;29(11):1377-85. DOI: 10.1093/eurheartj/ehn153

Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer Viewpoint of the IARC Working Group. N Engl J Med [Internet]. 2016 Aug 25;375(8):794-8. DOI: 10.1056/NEJMsr1606602

Libby P, Sidlow R, Lin AE, et al. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: Review Topic of the Week. JACC [Internet]. 2019 Jul 30;74(4):567-577. DOI: 10.1016/j.jacc.2019.06.007

Poynter JN, Gruber SB, Higgins P, et al. Statins and the risk of colorectal cancer. N Engl J Med [Internet]. 2005 May 26;352(21):2184-92. DOI: 10.1056/NEJMoa043792

Lancellotti P, Marechal P, Donis N, et al. Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. Eur Heart J [Internet]. 2019 Dec 21;40(48):3910-3912. DOI: 10.1093/eurheartj/ehz645

Van Kruijsdijk RC, van der Graaf Y, Peeters PH, et al. Cancer risk in patients with manifest vascular disease: effects of smoking, obesity, and metabolic syndrome. Cancer Epidemiol Biomarkers Prev [Internet]. 2013 Jul;22(7):1267-77. DOI: 10.1158/1055-9965.EPI-13-0090

Hasin T, Gerber Y, Weston SA, Jiang R, et al. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. JACC [Internet]. 2016 Jul 19;68(3):265-271. DOI: 10.1016/j.jacc.2016.04.053.

Van’t Klooster CC, Ridker PM, Hjortnaes J, et al. The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. Eur Heart J [Internet]. 2019 Dec 21;40(48):3901-3909. DOI: 10.1093/eurheartj/ehz587

Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2017 Oct 21;390(10105):1833-1842. DOI: 10.1016/S0140-6736(17)32247-X

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J [Internet]. 2016 Sep 21;37(36):2768-2801. DOI: 10.1093/eurheartj/ehw211

Plana JC, Galderisi M, Barac A, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr [Internet]. 2014 Sep;27(9):911-39. DOI: 10.1016/j.echo.2014.07.012

Pérez IE, Taveras Alam S, Hernández GA, et al. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol [Internet]. 2019 Jul 29;13:1179546819866445. DOI: 10.1177/1179546819866445

Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail [Internet]. 2020 Nov;22(11):1945-1960. DOI: 10.1002/ejhf.1920

Celutkien J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail [Internet]. 2020 Sep;22(9):1504-1524. DOI: 10.1002/ejhf.1957

Medvedofsky D, Mor-Avi V, Amzulescu M, et al. Three-dimensional echocardiographic quantification of the left-heart chambers using an automated adaptive analytics algorithm: multicentre validation study. Eur Heart J Cardiovasc Imaging [Internet]. 2018 Jan 1;19(1):47-58. DOI: 10.1093/ehjci/jew328

Frey MK and Bergler-Klein J. Echocardiographic evaluation of patients undergoing cancer therapy. Eur Heart J Cardiovasc Imaging [Internet]. 2021 Mar 22;22(4):375-382. DOI: 10.1093/ehjci/jeaa341

Rosmini S, Aggarwal A, Chen DH, et al. Cardiac computed tomography in cardio-oncology: an update on recent clinical applications. Eur Heart J Cardiovasc Imaging [Internet]. 2021 Mar 22;22(4):397-405. DOI: 10.1093/ehjci/jeaa351

Sawaya H, Sebag IA, Plana JC, et al. Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated with Anthracyclines, Taxanes, and Trastuzumab. Circ Cardiovasc Imaging [Internet]. 2012 Sep 1;5(5):596-603. DOI: 10.1161/CIRCIMAGING.112.973321

Pudil R, Mueller C, Celutkiene J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail [Internet]. 2020 Nov;22(11):1966-1983. DOI: 10.1002/ejhf.2017

Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. JACC [Internet]. 2017 Nov 14;70(20):2536-2551. DOI: 10.1016/j.jacc.2017.09.1096

Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail [Internet]. 2018 Dec;20(12):1721-1731. DOI: 10.1002/ejhf.1292

Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation [Internet]. 2015 Jun 2;131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777

Thavendiranathan P, Negishi T, Somerset E, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. JACC [Internet]. 2021 Feb 2;77(4):392-401. DOI: 10.1016/j.jacc.2020.11.020

Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail [Internet]. (2016) 37, 2129–2200. DOI: 10.1002/ejhf.592

Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J [Internet]. 2019 Jun 7;40(22):1756-1763. DOI: 10.1093/eurheartj/ehy453